Attenuation of Antioxidant Capacity in Human Breast Cancer Cells by Carbon Monoxide through Inhibition of Cystathionine β‑Synthase Activity: Implications in Chemotherapeutic Drug Sensitivity

• Published in: Journal of medicinal chemistry Vol. 60; no. 19; pp. 8000 - 8010
• Main Authors: Kawahara, Brian, Moller, Travis, Hu-Moore, Kayla, Carrington, Samantha, Faull, Kym F, Sen, Suvajit, Mascharak, Pradip K
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 12.10.2017
• Subjects: Antibiotics, Antineoplastic - pharmacology; Antineoplastic Agents - chemical synthesis; Antineoplastic Agents - pharmacology; Antioxidants - metabolism; Breast Neoplasms - metabolism; Carbon Monoxide - metabolism; Cell Line, Tumor; Cystathionine beta-Synthase - antagonists & inhibitors; Doxorubicin - pharmacology; Drug Synergism; Female; Gene Silencing - drug effects; Glutathione - metabolism; Humans; NF-E2-Related Factor 2 - metabolism
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.7b00476

Drug resistance is a major impediment to effective treatment of breast cancer. Compared to normal cells, cancer cells have an increased antioxidant potential due to an increased ratio of reduced to oxidized glutathione (GSH/GSSG). This is known to confer therapeutic resistance. Here, we have identified a mechanism, unique to breast cancer cells, whereby cystathionine β-synthase (CBS) promotes elevated GSH/GSSG. Lentiviral silencing of CBS in human breast cancer cells attenuated GSH/GSSG, total GSH, nuclear factor erythroid 2-related factor 2 (Nrf2), and processes downstream of Nrf2 that promote GSH synthesis and regeneration of GSH from GSSG. Carbon monoxide (CO) reduced GSH/GSSG in three breast cancer cell lines by inhibiting CBS. Furthermore, CO sensitized breast cancer cells to doxorubicin. These results provide insight into mechanism(s) by which CBS increases the antioxidant potential and the ability for CO to inhibit CBS activity to alter redox homeostasis in breast cancer, increasing sensitivity to a chemotherapeutic.